Using a retrospective analysis we compared 79 recipients of cadaveric renal allografts who were treated with cyclosporine as the sole initial immunosuppressant and 29 concurrent transplant recipients treated with conventional immunosuppressants. The cyclosporine-treated group had a slightly higher actuarial patient survival at four years (86 per cent v. 76 per cent). Actuarial graft survival at four years was 70 per cent in the cyclosporine group, as compared with 62 per cent in the conventionally immunosuppressed group. The incidence of acute rejection episodes was 62.1 per cent in the former and 65.5 per cent in the latter. Nephrotoxicity was managed either by reduction of the dose of cyclosporine or by conversion to conventional immunosuppression. Monitoring of trough serum levels of cyclosporine facilitated its administration. Serum creatinine levels have been higher in cyclosporine-treated patients with functioning grafts, but graft deterioration has not occurred after more than three years. Cyclosporine provides adequate immunosuppression for patients with renal allografts. At four years, the rates of patient and graft survival remain superior to those with conventional immunosuppression. In 41 per cent of patients the use of steroids was completely avoided. The longer-term results of this powerful immunosuppressive agent are not yet known.
This article has been cited by other articles:
Gee, I, Alexander, G
(2005). Liver transplantation for hepatitis C virus related liver disease. Postgrad. Med. J.
81: 765-771
[Abstract][Full Text]
Hariharan, S., Johnson, C. P., Bresnahan, B. A., Taranto, S. E., McIntosh, M. J., Stablein, D.
(2000). Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996. NEJM
342: 605-612
[Abstract][Full Text]
Shihab-Eldeen, A., Owunwanne, A., Junaid, T., Yacoub, T.
(1996). Experimental studies on multiorgan toxicity of cyclosporine-A in rats using a radiopharmaceutical and comparison with histopathological findings. Hum Exp Toxicol
15: 867-871
[Abstract]
Burke, J. F., Pirsch, J. D., Ramos, E. L., Salomon, D. R., Stablein, D. M., Van Buren, D. H., West, J. C.
(1994). Long-Term Efficacy and Safety of Cyclosporine in Renal-Transplant Recipients. NEJM
331: 358-363
[Abstract][Full Text]
Matis, W. L., Ellis, C. N., Griffiths, C. E. M., Lazarus, G. S.
(1992). Treatment of Pyoderma Gangrenosum With Cyclosporine. Arch Dermatol
128: 1060-1064
[Abstract]
Showstack, J., Katz, P., Amend, W., Salvatierra, O.
(1990). The Association of Cyclosporine With the 1-Year Costs of Cadaver-Donor Kidney Transplants. JAMA
264: 1818-1823
[Abstract]
Offner, G., Hoyer, P. F., Juppner, H., Krohn, H. P., Brodehl, J.
(1987). Somatic Growth After Kidney Transplantation: Beneficial Effect of Cyclosporine in Comparison With Conventional Immunosuppression. Arch Pediatr Adolesc Med
141: 541-546
[Abstract]
Spital, A., Spital, M., Spital, R.
(1986). The Living Kidney Donor: Alive and Well. Arch Intern Med
146: 1993-1996
[Abstract]
Svenson, K., Bohman, S.-O., Hallgren, R.
(1986). Renal Interstitial Fibrosis and Vascular Changes: Occurrence in Patients With Autoimmune Diseases Treated With Cyclosporine. Arch Intern Med
146: 2007-2010
[Abstract]
Ryffel, B., Mihatsch, M. J.
(1986). Cyclosporine Nephrotoxicity. Toxicol Pathol
14: 73-82
[Abstract]
Ellis, D., Avner, E. D., Rosenthal, J. T., Taylor, R. J., Young, L. W., Palumbi, M. A., Hakala, T. R.
(1985). Renal Function and Somatic Growth in Pediatric Cadaveric Renal Transplantation With Cyclosporine-Prednisone Immunosuppression. Arch Pediatr Adolesc Med
139: 1161-1167
[Abstract]
Handschumacher, R., Harding, M., Rice, J, Drugge, R., Speicher, D.
(1984). Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science
226: 544-547
[Abstract]
COHEN, D. J., LOERTSCHER, R., RUBIN, M. F., TILNEY, N. L., CARPENTER, C. B., STROM, T. B.
(1984). Cyclosporine: A New Immunosuppressive Agent for Organ Transplantation. ANN INTERN MED
101: 667-682
[Abstract]
Previous
